@article {2446,
	title = {Mill Trial of the New Bleaching Agent -THPS},
	journal = {Pulp \& Paper-Canada},
	volume = {110},
	number = {7},
	year = {2009},
	note = {ISI Document Delivery No.: 508TWTimes Cited: 0Cited Reference Count: 31Hu, T. Q. Williams, T. Schmidt, J. A. James, B. R. Cavasin, R. Lewing, D.},
	month = {Sep},
	pages = {37-42},
	type = {Article},
	abstract = {An eight-day mill. trial of adding tetrakis(hydroxymethyl)phosphonium sulfate (THPS) (at 1.0 kg THPS/t pulp) to hydrosulfite (Y) bleaching of spruce SGW pulp shows an average, additional brightness gain of 2.0-2.3 ISO points without any bleach plant or paper machine process upsets. This additional brightness gain, sustained during subsequent one-year commercial implementation of the "THPS + Y" bleaching technology, allows the mill to reach brightness target during the difficult summer period, and to reduce the consumption of expensive brightness-enhancing additives for LWC papers. Overall estimated cost saving to the mill is $250,000/year.},
	keywords = {bleach, bleaching, brightness, BRIGHTNESS STABILIZING AGENTS, CHEMISTRY, COMPOUNDS, COSTS, mechanical pulps, PHOSPHONIUM, SODIUM HYDROSULFITE, SULFATE, TERTIARY PHOSPHINES, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM},
	isbn = {0316-4004},
	url = {<Go to ISI>://000270960500008},
	author = {Hu, Thomas Q. and Williams, T. and Schmidt, J. A. and James, Brian R. and Cavasin, R. and Lewing, D.}
}
@article {2446,
	title = {Mill Trial of the New Bleaching Agent -THPS},
	journal = {Pulp \& Paper-Canada},
	volume = {110},
	number = {7},
	year = {2009},
	note = {ISI Document Delivery No.: 508TWTimes Cited: 0Cited Reference Count: 31Hu, T. Q. Williams, T. Schmidt, J. A. James, B. R. Cavasin, R. Lewing, D.},
	month = {Sep},
	pages = {37-42},
	type = {Article},
	abstract = {An eight-day mill. trial of adding tetrakis(hydroxymethyl)phosphonium sulfate (THPS) (at 1.0 kg THPS/t pulp) to hydrosulfite (Y) bleaching of spruce SGW pulp shows an average, additional brightness gain of 2.0-2.3 ISO points without any bleach plant or paper machine process upsets. This additional brightness gain, sustained during subsequent one-year commercial implementation of the "THPS + Y" bleaching technology, allows the mill to reach brightness target during the difficult summer period, and to reduce the consumption of expensive brightness-enhancing additives for LWC papers. Overall estimated cost saving to the mill is $250,000/year.},
	keywords = {bleach, bleaching, brightness, BRIGHTNESS STABILIZING AGENTS, CHEMISTRY, COMPOUNDS, COSTS, mechanical pulps, PHOSPHONIUM, SODIUM HYDROSULFITE, SULFATE, TERTIARY PHOSPHINES, TETRAKIS(HYDROXYMETHYL)PHOSPHONIUM},
	isbn = {0316-4004},
	url = {<Go to ISI>://000270960500008},
	author = {Hu, Thomas Q. and Williams, T. and Schmidt, J. A. and James, Brian R. and Cavasin, R. and Lewing, D.}
}
@article {2637,
	title = {Vanadium treatment of type 2 diabetes: A view to the future},
	journal = {Journal of Inorganic Biochemistry},
	volume = {103},
	number = {4},
	year = {2009},
	note = {ISI Document Delivery No.: 429EUTimes Cited: 20Cited Reference Count: 41Thompson, Katherine H. Lichter, Jay LeBel, Carl Scaife, Michael C. McNeill, John H. Orvig, Chris6th International Vanadium SymposiumJUL 17-19, 2008Lisbon, PORTUGALSp. Iss. SI},
	month = {Apr},
	pages = {554-558},
	type = {Proceedings Paper},
	abstract = {3-Hydroxy-2-methyl-4-pryone and 2-ethyl 3-hydroxy-4-pyrone (maltol and ethyl maltol, respectively) have proven especially suitable a ligands for vanadyl tons, fit potential insulin enhancing agents for diabetes mellitus. Both bis(maltolato)oxovanadium(IV) (BMOV), and the ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), have the desired intermediate stability for pro-drug use, and have undergone extensive pie-clinical testing for safety and efficacy. Pharmacokinetic evaluation indicates a pattern of biodistribution consistent with fairly rapid dissociation and uptake, binding to serum transferrin for systemic circulation and transport to tissues, with preferential uptake in bone. These bis-ligand oxovanadium(IV) (VOL2) compounds have a clear advantage over inorganic vanadyl sulfate in terms of bioavailability and pharmaceutical efficacy. BEOV has now completed Phase I and has advanced to Phase II clinical trials. In the Phase I trial, a ran-e of doses horn 10 mg, to 90 mg BEOV, given orally to non-diabetic volunteers, resulted in no adverse effects, all biochemical parameters remained within normal limits. In the Phase IIa trial, BEOV (AKP-020). 20 mg, daily for 28 clays, per os, in seven type 2 diabetic Subjects, was associated with reductions in fasting blood and glucose and \%HbA1c; improved responses to oral glucose tolerance testing, versus, the observed worsening of diabetic symptoms in the two placebo controls. (C) 2009 Elsevier Inc. All rights reserved.},
	keywords = {BIODISTRIBUTION, bis(ethylmaltolato)oxovanadium(IV), BIS(MALTOLATO)OXOVANADIUM(IV), CHEMISTRY, Diabetes mellitus, IN-VIVO, INSULIN SENSITIVITY, MALTOL, METAL-COMPLEXES, RATS, SERUM, SKELETAL-MUSCLE, SULFATE, VANADIUM},
	isbn = {0162-0134},
	url = {<Go to ISI>://000264904400011},
	author = {Thompson, K. H. and Lichter, J. and Lebel, C. and Scaife, M. C. and McNeill, J. H. and Orvig, Chris}
}
@article {524,
	title = {Influence of chelation and oxidation state on vanadium bioavailability, and their effects on tissue concentrations of zinc, copper, and iron},
	journal = {Biological Trace Element Research},
	volume = {86},
	number = {1},
	year = {2002},
	note = {ISI Document Delivery No.: 541ZTTimes Cited: 27Cited Reference Count: 45},
	month = {Apr},
	pages = {31-44},
	type = {Article},
	abstract = {Today, vanadium compounds are frequently included in nutritional supplements and are also being developed for therapeutic use in diabetes mellitus. Previously, tissue uptake of vanadium from bis(maltolato)oxovanadium(IV) (BMOV) was shown to be increased compared to its uptake from vanadyl sulfate (VS). Our primary objective was to test the hypothesis that complexation increases vanadium uptake and that this effect is independent of oxidation state. A secondary objective was to compare the effects of vanadium complexation and oxidation state on tissue iron, copper, and zinc. Wistar rats were fed either ammonium metavanadate (AMV), VS, or BMOV (1.2 mM each in the drinking water). Tissue uptake of V following 12 wk of BMOV or AMV was higher than that from VS (p < 0.05). BMOV led to decreased tissue Zn and increased bone Fe content. The same three compounds were compared in a cellular model of absorption (Caco-2 cells). Vanadium uptake from VS was higher than that from BMOV or AMV at 10 min, but from BMOV (250 \&mu;M only, 60 min), uptake was far greater than from AMV or VS. These results show that neither complexation nor oxidation state alone are adequate predictors of relative absorption, tissue accumulation, or trace element interactions.},
	keywords = {ABSORPTION, BIS(MALTOLATO)OXOVANADIUM(IV), bone, CACO-2, Caco-2 cells, COMPLEXES, DIABETIC RATS, GLUCOSE-METABOLISM, IN-VITRO, INSULIN, kidney, ORTHO-VANADATE, skeletal muscle, SULFATE, VANADIUM, zinc},
	isbn = {0163-4984},
	url = {<Go to ISI>://000175018100004},
	author = {Thompson, K. H. and Tsukada, Y. and Xu, Z. M. and Battell, M. and McNeill, J. H. and Orvig, Chris}
}
@article {508,
	title = {Reduction of [VO2(ma)(2)](-) and [VO2(ema)(2)](-) by ascorbic acid and glutathione: Kinetic studies of pro-drugs for the enhancement of insulin action},
	journal = {Inorganic Chemistry},
	volume = {41},
	number = {6},
	year = {2002},
	note = {ISI Document Delivery No.: 532TZTimes Cited: 38Cited Reference Count: 31},
	month = {Mar},
	pages = {1357-1364},
	type = {Article},
	abstract = {{To shed light on the role of V(V) complexes as pro-drugs for theirV(IV) analogues, the kinetics of the reduction reactions of [VO2(ma)(2)](-) or [VO2(ema)(2)](-) (Hma = maltol},
	keywords = {AGENT BIS(MALTOLATO)OXOVANADIUM(IV) BMOV, CHEMISTRY, COMPLEXES, DIABETIC RATS, GLUCOSE-LOWERING PROPERTIES, LIGANDS, MIMETIC AGENT, SULFATE, VANADATE, VANADIUM COMPOUNDS},
	isbn = {0020-1669},
	url = {<Go to ISI>://000174492300008},
	author = {Song, B. and Aebischer, N. and Orvig, Chris}
}
@article {4616,
	title = {Vanadium complexes as insulin mimetic agents: Coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolinate, thiazolinate, or picolinate units},
	journal = {Inorganic Chemistry},
	volume = {38},
	number = {10},
	year = {1999},
	note = {ISI Document Delivery No.: 199BHTimes Cited: 72Cited Reference Count: 34},
	month = {May},
	pages = {2288-2293},
	type = {Article},
	abstract = {{The synthesis and characterization of four complexes containing naturally occurring binding groups are reported: VO(pic)(2). H2O (Hpic = picolinic or pyridine-2-carboxylic acid), NH4[VO2(pic)(2)]. 2H(2)O, VO(oz)(2) (Hoz = 2-(2{\textquoteright}- hydroxyphenyl)-2-oxazoline), and VO(thoz)(2) (Hthoz = 2-(2{\textquoteright}-hydroxyphenyl)-2-thiazoline). The X-ray structures of [NH4[VO2(pic)(2)]. 2H(2)O, VO(oz)(2), and VO(thoz)(2) have been determined. Crystals of NH4[VO2(pic)(2)]. 2H(2)O (C12H12N3O6V . 2H(2)O) are monoclinic, space group Cc, a 10.347(2) Angstrom},
	keywords = {BIS(MALTOLATO)OXOVANADIUM(IV), BMOV, CRYSTAL-STRUCTURE, DIABETIC RATS, GLUCOSE, NMR, SIDEROPHORE, SULFATE, SYSTEM, VANADATE},
	isbn = {0020-1669},
	url = {<Go to ISI>://000080459200009},
	author = {Melchior, M. and Thompson, K. H. and Jong, J. M. and Rettig, S. J. and Shuter, E. and Yuen, V. G. and Zhou, Y. and McNeill, J. H. and Orvig, Chris}
}
@article {4168,
	title = {Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats},
	journal = {American Journal of Physiology-Endocrinology and Metabolism},
	volume = {272},
	number = {1},
	year = {1997},
	note = {ISI Document Delivery No.: WG568Times Cited: 14Cited Reference Count: 39},
	month = {Jan},
	pages = {E30-E35},
	type = {Article},
	abstract = {In association with the insulin-mimetic properties, vanadium and related compounds have been shown to normalize hyperphagia associated with diabetes mellitus. The objective of this study was to clarify the effects of an organic vanadium compound, bis(maltolato)oxovanadium(IV) (BMOV), vs. food restriction on the metabolic abnormalities that occur in diabetes. BMOV was administered daily in drinking water to streptozotocin (STZ)-diabetic rats for 6 wk. Pair-fed groups were fed based on the intake for their respective counterparts from the previous day. Plasma parameters mere measured weekly after a carefully controlled 5-h fasting period. BMOV reduced plasma glucose (diabetic = 31.2 +/- 1.9, diabetic treated = 10.2 +/- 1.8, and diabetic pair fed = 34.2 +/- 1.1 mM), triglyceride, and cholesterol levels to normal without a concomitant increase in plasma insulin levels. There was no body weight gain in the diabetic pair-fed group compared with all other groups. BMOV but not pair feeding was effective in preventing the decreased cardiac function observed in STZ-diabetic rats. These data suggest that the glucose-lowering properties of BMOV are independent of the effects of dietary restriction and reinforce the efficacy of BMOV as an effective antihyperglycemic agent.},
	keywords = {diabetes, FA/FA, GLUCOSE-HOMEOSTASIS, glucose-lowering effect, HYPERINSULINEMIA, IN-VIVO, INSULIN SENSITIVITY, LONG-TERM IMPROVEMENT, MELLITUS, ORAL VANADATE, RATS, SPONTANEOUSLY HYPERTENSIVE RATS, STREPTOZOTOCIN, SULFATE, VANADYL},
	isbn = {0193-1849},
	url = {<Go to ISI>://A1997WG56800005},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
@article {3690,
	title = {Characterization of the potent insulin mimetic agent bis(maltolato)oxovanadium(IV) (BMOV) in solution by EPR spectroscopy},
	journal = {Inorganic Chemistry},
	volume = {35},
	number = {22},
	year = {1996},
	note = {ISI Document Delivery No.: VP449Times Cited: 63Cited Reference Count: 48},
	month = {Oct},
	pages = {6507-6512},
	type = {Article},
	abstract = {{Bis(maltolato)oxovanadium(IV) (abbreviated BMOV or VO(ma)(2)) has been characterized by electron paramagnetic resonance (EPR) spectroscopy in CH2Cl2, H2O, MeOH, and pyridine at both room and low temperatures. Spin Hamiltonian parameters for mono- and bis(maltolato)oxovanadium(IV) complexes [VO(ma)](+) (=[VO(ma)(H2O)(n)](+)},
	keywords = {ADIPOCYTES, CHEMISTRY, DIABETIC RATS, ELECTRON-PARAMAGNETIC-RES, FUTURE, GLUCOSE, KINASE, MIMICS, SULFATE, treatment, VANADYL COMPLEXES},
	isbn = {0020-1669},
	url = {<Go to ISI>://A1996VP44900022},
	author = {Hanson, G. R. and Sun, Y. and Orvig, Chris}
}
@article {3578,
	title = {COMPARISON OF THE GLUCOSE-LOWERING PROPERTIES OF VANADYL SULFATE AND BIS(MALTOLATO)OXOVANADIUM(IV) FOLLOWING ACUTE AND CHRONIC ADMINISTRATION},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {73},
	number = {1},
	year = {1995},
	note = {ISI Document Delivery No.: QN264Times Cited: 71Cited Reference Count: 31},
	month = {Jan},
	pages = {55-64},
	type = {Article},
	abstract = {Numerous studies, bath in vitro and in vivo, have demonstrated the insulin-mimetic properties of vanadium. Chronic oral administration of inorganic and organic compounds of both vanadium(IV) and vanadium(V) reduced plasma glucose levels and restored plasma lipid levels in streptozotocin-diabetic rats. We investigated the acute effects of both vanadyl sulfate and bis(maltolato)oxovanadium(IV) (BMOV), an organic vanadium compound, on plasma glucose levels by several routes of administration. Previous studies have shown that chronic administration of vanadyl sulfate has resulted in a sustained euglycemia following withdrawal of the drug. This effect was not observed following the chronic administration of BMOV; therefore, we investigated the effect of increasing the concentration of BMOV on the production of a sustained euglycemic response. An acute plasma glucose lowering effect was obtained with both vanadyl sulfate and BMOV when administered as a single dose by either oral gavage or intraperitoneal injection. In those animals that responded to vanadium treatment, plasma glucose levels were within the normal range within 2 to 6 h when given by i.p. injection or within 4 to 8 h when given by oral gavage. BMOV-treated rats that responded to treatment maintained the euglycemic effect for extended periods, ranging from 1 to 14 weeks following administration. However, vanadyl sulfate treated rats reverted to hyperglycemia within 12 to 24 h, depending on the route of administration. Intravenous administration of BMOV was effective in lowering plasma glucose levels only when administered by continuous infusion. An oral dose - response curve showed that BMOV was 2 to 3 times as potent as vanadyl sulfate. This difference in potency was observed with both oral and intraperitoneal administration, which suggests that the increase in potency with BMOV cannot be totally attributed to increased gastrointestinal absorption. Organic chelation of vanadium may facilitate uptake into vanadium-sensitive tissues. Chronic oral administration of higher concentrations of BMOV did not result in a sustained reduction in plasma glucose following withdrawal of the drug. All diabetic rats eventually responded to increased concentrations of BMOV with a restoration of plasma glucose levels to normal values; however, reversion to the hyperglycemic state occurred within 2 days of withdrawal of treatment. Chronic oral administration of BMOV did not produce a sustained euglycemic effect following withdrawal, but acute administrations of the compound by either oral gavage or intraperitoneal injection did produce a long-term reduction in plasma glucose levels. Rats treated chronically with vanadyl sulfate remained euglycemic even after the drug was withdrawn. However, acute treatment produced only a transient euglycemia.},
	keywords = {ACUTE, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, DOSE RESPONSE, GAVAGE, HOMEOSTASIS, IMPROVEMENT, INDUCED DIABETIC RATS, INSULIN, STREPTOZOTOCIN DIABETIC, SULFATE, VANADYL},
	isbn = {0008-4212},
	url = {<Go to ISI>://A1995QN26400008},
	author = {Yuen, V. G. and Orvig, Chris and McNeill, J. H.}
}
@article {2941,
	title = {IMPROVEMENT IN CARDIAC DYSFUNCTION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS FOLLOWING CHRONIC ORAL-ADMINISTRATION OF BIS(MALTOLATO)OXOVANADIUM(IV)},
	journal = {Canadian Journal of Physiology and Pharmacology},
	volume = {71},
	number = {3-4},
	year = {1993},
	note = {ISI Document Delivery No.: LN775Times Cited: 70Cited Reference Count: 40},
	month = {Mar-Apr},
	pages = {270-276},
	type = {Article},
	abstract = {Decreased cardiac function in streptozotocin-diabetic rats has been used as a model of diabetes-induced cardiomyopathy, which is a secondary complication in diabetic patients. The present study was designed to evaluate the therapeutic effect of a new organic vanadium complex, bis(maltolato)oxovanadium(IV), (BMOV), in improving heart function in streptozotocin-diabetic rats. There were four groups of male, Wistar rats: control (C), control treated (CT), diabetic (D), and diabetic treated (DT). Treatment consisted of BMOV, 0.5 mg/mL (1.8 mM) for the first 3 weeks and 0.75 mg/mL (2.4 mM) for the next 22 weeks, in the drinking water of rats allowed ad libitum access to food and water. BMOV lowered blood glucose to < 9 mM in 70\% of DT animals without any increase in plasma insulin levels, and mean blood glucose and plasma lipid levels were significantly lower in DT vs. D rats. Tissue vanadium levels were measured in plasma, bone, kidney, liver, muscle, and fat of BMOV-treated rats. Plasma vanadium levels averaged 0.84 +/- 0.07 mug/mL (16.8 muM) in CT rats and 0.76 +/-0.05 mug/mL (15.2 muM) in DT animals. The highest vanadium levels at termination of this chronic feeding study were in bone, 18.3 +/- 3.0 mug/g (0.37 mumol/g) in CT and 26.4 +/- 2.6 mug/g (0.53 mumol/g) in DT rats, with intermediate levels in kidney and liver, and low, but detectable levels in muscle and fat. There were no deaths in either the CT or DT group, and no overt signs of vanadium toxicity were present. Tissue vanadium levels were not correlated with die glucose-lowering effect. Isolated working heart parameters of left ventricular developed pressure (LVDP) and rate of pressure development (+dP/dT, and -dP/dT) indicated that BMOV treatment resulted in significant correction of the heart dysfunction associated with streptozotocin-induced diabetes in rat.},
	keywords = {ACTIVATION, BIS(MALTOLATO)OXOVANADIUM(IV), BLOOD-GLUCOSE, diabetes, GLUCOSE-HOMEOSTASIS, INSULIN, MYOCARDIAL DYSFUNCTION, STREPTOZOTOCIN, SULFATE, VANADATE TREATMENT, VANADIUM},
	isbn = {0008-4212},
	url = {<Go to ISI>://A1993LN77500014},
	author = {Yuen, V. G. and Orvig, Chris and Thompson, K. H. and McNeill, J. H.}
}
